Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess
The present comparative observational study indicates that these inhibitors are associated with both common and specific adverse reactions, as documented in ADR reports. Clinicians should formulate individualized treatment plans that consider the adverse reactions linked to various drugs and the specific conditions of each patient, thereby promoting the rational use of these costly medications.
Authors
- Chenghao Xu
- Hua Luo (ORCID: https://orcid.org/0000-0002-2198-9204)
- Lü Liang (ORCID: https://orcid.org/0000-0002-9892-8346)
- Jiangjie Chen (ORCID: https://orcid.org/0000-0002-2613-0386)
- Liwei Zhang (ORCID: https://orcid.org/0000-0002-7674-9566)
- Shaohua Fan (ORCID: https://orcid.org/0009-0005-5031-8724)
- Youfu He (ORCID: https://orcid.org/0000-0003-4926-1706)
- Jing Zhu
Institutions
- Nanjing University of Chinese Medicine (CN)
- Wenzhou Medical University (CN)
- Guizhou Provincial People's Hospital (CN)
- Zhejiang Taizhou Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.3389/fphar.2025.1534802
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- National Natural Science Foundation of China